Review
Open access
Sep 2026
SGLT2 inhibitors in chronic kidney disease: cardiorenal outcomes, safety, and implementation in primary care
SGLT2 inhibitors are foundational therapies for CKD, providing consistent renal and cardiovascular benefits with an acceptable safety profile in patients with and without diabetes, however, substantial gaps remain in their implementation in primary care.
Shamsun Nahar, S. Haque, Sananda Halder
· Exploration of Cardiology · 0 citations